ESMO 2020

Feb 14, 2019

The Epic Sciences team presented at the virtual ESMO 2020 Annual Meeting from September 19 – 21, 2020.  

Thursday, February 14th – 11:30 AM-1:00 PM and 5:30 PM–6:30 PM

Poster Session A: Prostate Cancer and Trials in Progress.

Board K4 – Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC.

Authors: Howard Scher, MD, FASCO et al.

Board N4 – A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.

Authors: Simon Chowdhury, MD, PhD et al.

Friday, February 15th – 12:15 PM-1:45 PM and 5:15 PM–6:15 PM

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers.

Board F14 – Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).

Authors: Zishuo Hu et al.

Board G11 – Circulating cellular biomarkers associated with delayed time to progression among bladder cancer patients treated with immune checkpoint inhibitors.

Authors: Vadim Koshkin, MD et al.